ID: ALA4763673

Max Phase: Preclinical

Molecular Formula: C19H19F2N3O3

Molecular Weight: 375.38

Molecule Type: Unknown

Associated Items:

Representations

Canonical SMILES:  COc1cc(F)c([C@@H]2CNC(=O)[C@H]2NC(=O)Nc2ccc(C)cc2)c(F)c1

Standard InChI:  InChI=1S/C19H19F2N3O3/c1-10-3-5-11(6-4-10)23-19(26)24-17-13(9-22-18(17)25)16-14(20)7-12(27-2)8-15(16)21/h3-8,13,17H,9H2,1-2H3,(H,22,25)(H2,23,24,26)/t13-,17-/m0/s1

Standard InChI Key:  JDZYRVFPDFZSMG-GUYCJALGSA-N

Associated Targets(Human)

FPR2 Tchem Lipoxin A4 receptor (3472 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
FPR1 Tchem Formyl peptide receptor 1 (1372 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Mus musculus (284745 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 375.38Molecular Weight (Monoisotopic): 375.1394AlogP: 2.69#Rotatable Bonds: 4
Polar Surface Area: 79.46Molecular Species: NEUTRALHBA: 3HBD: 3
#RO5 Violations: 0HBA (Lipinski): 6HBD (Lipinski): 3#RO5 Violations (Lipinski): 0
CX Acidic pKa: 13.13CX Basic pKa: CX LogP: 2.35CX LogD: 2.35
Aromatic Rings: 2Heavy Atoms: 27QED Weighted: 0.77Np Likeness Score: -0.77

References

1. Asahina Y,Wurtz NR,Arakawa K,Carson N,Fujii K,Fukuchi K,Garcia R,Hsu MY,Ishiyama J,Ito B,Kick E,Lupisella J,Matsushima S,Ohata K,Ostrowski J,Saito Y,Tsuda K,Villarreal F,Yamada H,Yamaoka T,Wexler R,Gordon D,Kohno Y.  (2020)  Discovery of BMS-986235/LAR-1219: A Potent Formyl Peptide Receptor 2 (FPR2) Selective Agonist for the Prevention of Heart Failure.,  63  (17): [PMID:32407089] [10.1021/acs.jmedchem.9b02101]
2. Maciuszek M, Cacace A, Brennan E, Godson C, Chapman TM..  (2021)  Recent advances in the design and development of formyl peptide receptor 2 (FPR2/ALX) agonists as pro-resolving agents with diverse therapeutic potential.,  213  [PMID:33486199] [10.1016/j.ejmech.2021.113167]

Source